Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

Summary

This randomized phase II trial studies how well pembrolizumab works in treating patients with high risk oral intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2017-06-14

Primary completion

2025-07-14

Completion

2025-07-14

Drugs

Indications